ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained…
Author ONA Webmaster
ONA Webmaster
Creating outstanding digital resources tailored for the Australian Oncology community, including independent news and a dedicated job portal.
ASCO 2026: EMERALD-3 study shows that new combination treatment strategies for embolization-eligible hepatocellular carcinoma are superior
Results from the Phase 3 EMERALD-3 study found that combining the standard treatment of transarterial…
ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage RET fusion-positive NSCLC
Adjuvant treatment with the targeted therapy drug selpercatinib can help reduce the risk that cancer…
ASCO 2026: More accessible oral chemotherapy and ultra-low-dose immunotherapy combo may improve survival and reduce side effects for advanced head and neck cancer
Results from a new study out of India found that triple oral metronomic chemotherapy combined…
ASCO 2026: Some breast cancer patients with sentinel lymph node spread can safely skip axillary lymph node dissection
Results from the phase 3 SENOMAC clinical trial found that omitting an axillary lymph node dissection (ALND)…
ASCO 2026: Combining targeted immunotherapies with standard R-CHOP delays progression of aggressive B-cell lymphomas
Results from the phase III frontMIND trial show that adding tafasitamab and lenalidomide to R-CHOP…
ASCO 2026: Galleri early detection test may shift timing of cancer detection, reducing stage IV diagnoses
Results from the first randomized controlled trial of a multi-cancer early detection (MCED) test suggest…
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
The CAPTURE breast cancer clinical trial has concluded that current standard of care, chemotherapy with…
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained…
ASCO 2026: Digital symptom monitoring with nurse support helps maintain quality of life in advanced cancer
A digital symptom monitoring program supported by palliative care nurses helped maintain quality of life…